Document Detail

Efficacy of aspirin for secondary prevention in patients with peripheral artery disease.
MedLine Citation:
PMID:  19814663     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Evaluation of: Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301, 1909-1919 (2009). Aspirin decreases the risk of cardiovascular events in patients with prior coronary heart or cerebrovascular disease. The American College of Cardiology/American Heart Association guidelines recommend a low-dose aspirin regimen (75-325 mg/day) to reduce the risk of cardiovascular events in patients with peripheral artery disease (PAD). However, the effect of aspirin for secondary prevention in patients with PAD has not been well established. The paper under evaluation performed a meta-analysis of 18 trials to investigate the effect of aspirin on cardiovascular events (nonfatal myocardial infarction, nonfatal stroke and cardiovascular death) in patients with PAD. The results of this meta-analysis in a PAD cohort revealed that treatment with aspirin did not significantly reduce the combined end point of cardiovascular events; however, aspirin resulted in a significant reduction in the incidence of nonfatal stroke. This analysis raises a number of questions regarding the overall efficacy of aspirin in PAD and what should be the optimal antiplatelet therapy in patients with PAD: aspirin, clopidogrel or perhaps a combination of aspirin and clopidogrel.
Dmitriy N Feldman; Issam D Moussa
Related Documents :
16088663 - Acute myocardial ischemia and infarction: making the right decisions in antithrombotic ...
18549843 - Relation of low response to clopidogrel assessed with point-of-care assay to periproced...
17612673 - Clinical characteristics, cardiac events and coronary angiographic findings in the pros...
Publication Detail:
Type:  Comment; Journal Article    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  7     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-09     Completed Date:  2010-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1203-7     Citation Subset:  -    
Greenberg Division of Cardiology, New York Presbyterian Hospital, Weill Cornell Medical College, Greenberg Division of Cardiology, Starr-434 Pavilion, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Comment On:
JAMA. 2009 May 13;301(18):1909-19   [PMID:  19436018 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cangrelor: a review on its mechanism of action and clinical development.
Next Document:  Anticoagulation for heart failure: selecting the best therapy.